Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00351975 · ClinicalTrials.gov registry record · Phase 1
Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases
A Phase 1 study of Chronic Myelomonocytic Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 56
- Enrollment target
- 4
- Study locations
NCT00351975 is a Phase 1 study of Chronic Myelomonocytic Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 56 participants, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT00351975, a Phase 1 study of Chronic Myelomonocytic Leukemia and Chronic Myelogenous Leukemia, BCR-ABL1 Positive, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 56 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the cancer. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving belinostat together with azacitidine may kill more cancer cells.
Conditions Studied
Interventions
- DRUG Azacitidine
- OTHER Laboratory Biomarker Analysis
- DRUG Belinostat
Study Locations (4)
Illinois
- University of Chicago Comprehensive Cancer Center - Chicago
Wisconsin
- University of Wisconsin Hospital and Clinics - Madison
Ontario
- University Health Network-Princess Margaret Hospital - Toronto
Canterbury
- Princess Margaret Hospital - Cashmere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-06 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00351975
The ClinicalTrials.gov registry entry for NCT00351975 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 88-participant average among 73 other Chronic Myelomonocytic Leukemia trials with a reported enrollment target (36% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Azacitidine is the first listed.
NCT00351975 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Illinois, Wisconsin, Ontario.
Frequently Asked Questions
What is clinical trial NCT00351975 about?
NCT00351975 is a clinical study titled "Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases". This phase I trial is studying the side effects and best dose of belinostat when given together with azacitidine in treating patients with advanced hematologic cancers or other diseases. Belinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by bloc...
What is the current status of trial NCT00351975?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 56 participants. The study started on 2006-06. Estimated completion is 2013-03.
What conditions does trial NCT00351975 study?
This clinical trial studies the following conditions: Chronic Myelomonocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative.
What interventions are being tested in trial NCT00351975?
The interventions under investigation include: Azacitidine (DRUG), Laboratory Biomarker Analysis (OTHER), Belinostat (DRUG).
Who is sponsoring clinical trial NCT00351975?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00351975 being conducted?
This trial has 4 study locations across Illinois, Wisconsin, Ontario, Canterbury. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RECRUITING · Phase 1
-
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RECRUITING · Phase 1
-
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
RECRUITING · Phase 1
-
Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.
RECRUITING · Phase 1
-
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
RECRUITING · Phase 1
Explore more on PlainTrial
Chronic Myelomonocytic Leukemia
All registered trials for this condition
Chronic Myelogenous Leukemia, BCR-ABL1 Positive
All registered trials for this condition
Illinois
All trials with a study site in Illinois
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.